US FDA SOP seeks to convey new regulatory expectations to medtech firms faster
This article was originally published in RAJ Devices
Executive Summary
The US Food Drug Administration is seeking feedback on a procedure that it expects will help its devices unit clarify and communicate to stakeholders more quickly any changes in its regulatory expectations that could affect data submitted as part of a pre-market submission or an investigational device exemption1,2.